Associated Papers
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A et al.
Cancer Discovery, 2022
35404998 (PubMed )
Supplement: cd-22-0158_supplementary_tables_suppst1-st7.docx
Select a paper to view details